AstraZeneca signs CSPC China deal for experimental kidney disease drugs (updated)
UPDATE 1-AstraZeneca signs CSPC China deal for experimental kidney disease drugs adding details of deal and context
July 2 (Reuters) - AstraZeneca AZN.L has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group 1093.HK to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday.
CSPC's Hong Kong stock exchange filing did not disclose the specific diseases the medicines would target. The World Health Organization says an estimated 674 million people worldwide have chronic kidney disease, which progresses gradually.
AstraZeneca will have the option to obtain exclusive rights to develop, manufacture and commercialise one preclinical small nucleic acid drug candidate globally, and a second outside China
CSPC is eligible to receive $30 million as an upfront payment and up to about $1.74 billion in additional payments tied to development and sales-related milestones
AstraZeneca has previously entered into collaborations with CSPC, including on obesity and weight-related conditions
AstraZeneca declined to comment on what diseases would be targeted under the new CSPC deal
(Reporting by Andrew Silver in Shanghai and Sherin Sunny in Bengaluru; Editing by Alexander Smith)
((andrew.silver@thomsonreuters.com))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines